ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2842

Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control

Sangmee Bae1, Ilana Golub 2, Jennifer Wang 3, Ani Shahbazian 2, Srinivasa Reddy 3 and Christina Charles-Schoeman 4, 1UCLA, Los Angeles, CA, 2UCLA, Los Angeles, 3UCLA Medical Center, Los Angeles, 4University of California, Los Angeles, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Idiopathic Inflammatory Myopathies (IIM), lipids and PON1

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: 5T113: Muscle Biology, Myositis & Myopathies II (2840–2845)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Inflammation and damage to the vascular endothelium are implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM), particularly dermatomyositis. Paraoxonase 1 (PON1) is a high density lipoprotein (HDL)- associated enzyme, which normally protects the vascular endothelium from damage due to oxidized phospholipids, which accumulate under conditions of oxidative stress. The current work evaluates PON1 activity in IIM patients compared to healthy controls.

Methods: In a cross sectional analysis of 169 patients with IIM and 112 healthy controls we measured plasma PON1 activity using the arylesterase assay (Clin Chim Acta. 402(1-2):67-74, 2009). Lipoprotein cholesterol levels, inflammatory markers, and myositis autoantibodies(ab) were assessed by standard assays, and myositis disease activity was assessed using physician global 100 mm visual analogue scales (VAS) and CPK levels.

Results: Patients with IIM had significantly lower PON1 activity compared to healthy controls (Table 1). Univariate analysis of PON1 activity in IIM patients showed associations of lower PON1 activity with higher disease activity measured by VAS and CPK, as well as with the presence of antisynthetase antibodies (Table 2).  PON1 activity remained strongly associated with IIM diagnosis and myositis disease activity measures after multivariate adjustment for demographic factors (age, gender, race) and factors that were significantly different in univariate analysis (Table 3).

Conclusion: In a large cross sectional cohort of IIM patients, plasma PON1 activity was significantly lower than healthy controls of similar demographics, and was associated with myositis disease activity. Low PON1 activity has been previously associated with increased vascular risk and may warrant further investigation for its role in perpetuation of vascular damage in IIM patients.


PON1Table 1

*p<0.05 on chi-square test for categorical variables and Wilcoxon rank-sum test for continuous variables. ESR, erythrocyte sedimentation rate; hsCRP, high sensitivity C-Reactive Protein, CPK, creatine phosphokinase
# Ab testing available in 112 subjects


PON1Table 2

Median -IQR- unless specified
# avail in 161; ¶ avail in 171; ‡ avail in 168; § avail in 112


PON1Table 3

Model 1 including IIM and HC -N=281-, Model 2 including IIM only -N=169- with disease activity measured as VAS, Model 3 including IIM only with disease activity measured as CPK.
For Model 2, although Total cholesterol and HDL were both significant in univariate analysis, only HDL was included in the model as the two lipid variables were significantly correlated.


Disclosure: S. Bae, None; I. Golub, None; J. Wang, None; A. Shahbazian, None; S. Reddy, None; C. Charles-Schoeman, Abbvie, 2, AbbVie, 2, Amgen, 5, BMS, 2, Bristol Myers Squibb, 2, Gilead, 5, Octapharma, 2, 5, Pfizer, 2, 5, Regeneron, 5, Regeneron/Sanofi, 5, Sanofi, 5.

To cite this abstract in AMA style:

Bae S, Golub I, Wang J, Shahbazian A, Reddy S, Charles-Schoeman C. Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/paraoxonase-1-activity-is-abnormal-in-patients-with-idiopathic-inflammatory-myopathies-and-associates-with-poor-disease-control/. Accessed January 31, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/paraoxonase-1-activity-is-abnormal-in-patients-with-idiopathic-inflammatory-myopathies-and-associates-with-poor-disease-control/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences